Therefore, combining TGF-β inhibitors with anti-PD-1 or anti-PD-L1 has been proposed as a strategy to augment anti-tumor immune responses and enhance tumor eradication [343, 344]. The gene discussed is TGFB1; the disease is neoplasm.